AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trialnews2026-03-27T12:00:35+00:00March 27th, 2026|Endpoints News|
Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidatenews2026-03-27T11:21:39+00:00March 27th, 2026|Endpoints News|
Recursion appoints former Exelixis CMO; More executive moves at Incytenews2026-03-27T11:00:13+00:00March 27th, 2026|Endpoints News|
AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected populationnews2026-03-27T10:46:08+00:00March 27th, 2026|Endpoints News|
‘The truth is supremely valuable and we cannot lie our way to it’news2026-03-27T10:05:00+00:00March 27th, 2026|Chemistry World|
Steve Liddle: ‘Try and do something different to what everyone else is doing’news2026-03-27T09:43:00+00:00March 27th, 2026|Chemistry World|
